



UHID/MR No : SCHI.0000016438 Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 10:56AM

Reported : 27/Nov/2023 12:53PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF HAEMATOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324

PERIPHERAL SMEAR , WHOLE BLOOD EDTA

Page 1 of 15







Patient Name : Mr.ANUJ KUMAR

Age/Gender : 34 Y 3 M 9 D/M UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 10:56AM

Reported : 27/Nov/2023 12:53PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF HAEMATOLOGY

DELYACIMENT OF TIMEMORE					
ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

HEMOGRAM, WHOLE BLOOD EDTA						
HAEMOGLOBIN	15.3	g/dL	13-17	CYANIDE FREE COLOUROMETER		
PCV	47.70	%	40-50	PULSE HEIGHT AVERAGE		
RBC COUNT	5.53	Million/cu.mm	4.5-5.5	Electrical Impedence		
MCV	86.4	fL	83-101	Calculated		
MCH	27.7	pg	27-32	Calculated		
MCHC	32.1	g/dL	31.5-34.5	Calculated		
R.D.W	12.8	%	11.6-14	Calculated		
TOTAL LEUCOCYTE COUNT (TLC)	12,380	cells/cu.mm	4000-10000	Electrical Impedance		
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)	·				
NEUTROPHILS	75.8	%	40-80	Electrical Impedance		
LYMPHOCYTES	15.2	%	20-40	Electrical Impedance		
EOSINOPHILS	1.1	%	1-6	Electrical Impedance		
MONOCYTES	7.5	%	2-10	Electrical Impedance		
BASOPHILS	0.4	%	<1-2	Electrical Impedance		
ABSOLUTE LEUCOCYTE COUNT	•			•		
NEUTROPHILS	9384.04	Cells/cu.mm	2000-7000	Calculated		
LYMPHOCYTES	1881.76	Cells/cu.mm	1000-3000	Calculated		
EOSINOPHILS	136.18	Cells/cu.mm	20-500	Calculated		
MONOCYTES	928.5	Cells/cu.mm	200-1000	Calculated		
BASOPHILS	49.52	Cells/cu.mm	0-100	Calculated		
PLATELET COUNT	189000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY		
ERYTHROCYTE SEDIMENTATION RATE (ESR)	09	mm at the end of 1 hour	0-15	Modified Westergren		
PERIPHERAL SMEAR			_			

RBC NORMOCYTIC NORMOCHROMIC

WBC - MILD LEUCOCYTOSIS

PLATELETS ARE ADEQUATE ON SMEAR

NO HEMOPARASITES SEEN

Page 2 of 15







UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389
Ref Doctor : Dr.SELF

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 

 Collected
 : 27/Nov/2023 10:23AM

 Received
 : 27/Nov/2023 10:56AM

 Reported
 : 27/Nov/2023 04:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF HAEMATOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	А		Forward & Reverse Grouping with Slide/Tube Aggluti	
Rh TYPE	POSITIVE		Forward & Reverse Grouping with Slide/Tube Agglutination	

Page 3 of 15







Patient Name : Mr.ANUJ KUMAR

Age/Gender : 34 Y 3 M 9 D/M UHID/MR No : SCHI.000001643

UHID/MR No : SCHI.0000016438 Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 02:44PM

Received : 27/Nov/2023 04:00PM Reported : 27/Nov/2023 07:13PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324						
ANGOI LIMI - MILDIWITELE - I OLL BOD	ARCOPEMI - MEDIWHEEL - FULL BODT PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - F12324					
Test Name	Test Name Result Unit Bio. Ref. Range Method					
i est Naille	Resuit	Onit	Bio. Ref. Range	Method		

GLUCOSE, FASTING, NAF PLASMA	94	mg/dL	70-100	GOD - POD	
= = = = , = = , = = ,	-	J.			

#### **Comment:**

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

#### Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	109	mg/dL	70-140	GOD - POD
HOURS , SODIUM FLUORIDE PLASMA (2				
HR)				

#### **Comment:**

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 15





Ref Doctor





Patient Name : Mr.ANUJ KUMAR

Age/Gender : 34 Y 3 M 9 D/M

UHID/MR No : SCHI.0000016438

: Dr.SELF

Visit ID : SCHIOPV23389

Emp/Auth/TPA ID : 58963

Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 01:16PM Reported : 27/Nov/2023 03:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

# ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.1	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG),	100	mg/dL	Calculated
WHOLE BLOOD EDTA			

#### **Comment:**

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 - 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
  - A: HbF >25%
  - B: Homozygous Hemoglobinopathy.
  - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 15





UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 11:23AM Reported : 27/Nov/2023 07:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	V DI HE ANNHAL CI	HECK ADVANC	ED HC MALE TMT DA	AN INDIA EV2224
ARCOLLINI - MICDIANIELE - LOLL BOD	T PLUS ANNUAL CI	ILCK ADVANC	ED NO WALL - INT - FA	4N INDIA - 1 1 2324
Test Name	Result	Unit	Bio. Ref. Range	Method
	1100111			

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	191	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	223	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	52	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	139	mg/dL	<130	Calculated
LDL CHOLESTEROL	94.4	mg/dL	<100	Calculated
VLDL CHOLESTEROL	44.6	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.67		0-4.97	Calculated

#### **Comment:**

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199		≥ 500
III .I D1 .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 15







UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 11:23AM Reported : 27/Nov/2023 07:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

LIVER FUNCTION TEST (LFT), SERUM						
BILIRUBIN, TOTAL	0.80	mg/dL	0.20-1.20	DIAZO METHOD		
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.0-0.3	Calculated		
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	46	U/L	<50	Visible with P-5-P		
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	32.0	U/L	17-59	UV with P-5-P		
ALKALINE PHOSPHATASE	84.00	U/L	38-126	p-nitrophenyl phosphate		
PROTEIN, TOTAL	7.10	g/dL	6.3-8.2	Biuret		
ALBUMIN	4.30	g/dL	3.5 - 5	Bromocresol Green		
GLOBULIN	2.80	g/dL	2.0-3.5	Calculated		
A/G RATIO	1.54		0.9-2.0	Calculated		

#### **Comment:**

 $LFT\ results\ reflect\ different\ aspects\ of\ the\ health\ of\ the\ liver,\ i.e.,\ hepatocyte\ integrity\ (AST\ \&\ ALT),\ synthesis\ and\ secretion\ of\ bile\ (Bilirubin,\ ALP),\ cholestasis\ (ALP,\ GGT),\ protein\ synthesis\ (Albumin)$ 

Common patterns seen:

#### 1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

#### 2. Cholestatic Pattern:

- $\bullet$  ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- $\bullet \ To \ establish \ the \ hepatic \ origin \ correlation \ with \ GGT \ helps. \ If \ GGT \ elevated \ indicates \ hepatic \ cause \ of \ increased \ ALP.$

#### 3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.





Patient Name : Mr.ANUJ KUMAR

Age/Gender : 34 Y 3 M 9 D/M UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM
Received : 27/Nov/2023 11:23AM
Reported : 27/Nov/2023 07:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM						
CREATININE	0.90	mg/dL	0.66-1.25	Creatinine amidohydrolase		
UREA	29.40	mg/dL	19-43	Urease		
BLOOD UREA NITROGEN	13.7	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	7.30	mg/dL	3.5-8.5	Uricase		
CALCIUM	8.80	mg/dL	8.4 - 10.2	Arsenazo-III		
PHOSPHORUS, INORGANIC	3.30	mg/dL	2.5-4.5	PMA Phenol		
SODIUM	134	mmol/L	135-145	Direct ISE		
POTASSIUM	4.1	mmol/L	3.5-5.1	Direct ISE		
CHLORIDE	103	mmol/L	98 - 107	Direct ISE		

Page 8 of 15







UHID/MR No : SCHI.0000016438 Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM
Received : 27/Nov/2023 11:23AM
Reported : 27/Nov/2023 04:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT	OF BIG	OCHEMISTRY
------------	--------	------------

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324							
Test Name Result Unit Bio. Ref. Range Method							
				•			
ALKALINE PHOSPHATASE , SERUM	84.00	U/L	38-126	p-nitrophenyl phosphate			
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	39.00	U/L	15-73	Glyclyclycine Nitoranalide			

Page 9 of 15







UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 06:36PM Reported : 27/Nov/2023 09:02PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324							
Test Name Result Unit Bio. Ref. Range Method							

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM							
TRI-IODOTHYRONINE (T3, TOTAL)	0.91	ng/mL	0.7-2.04	CLIA			
THYROXINE (T4, TOTAL) 11.72 μg/dL 5.48-14.28 CLIA							
THYROID STIMULATING HORMONE (TSH)	1.943	μIU/mL	0.34-5.60	CLIA			

#### **Comment:**

Hor pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 15









Patient Name : Mr.ANUJ KUMAR

Age/Gender : 34 Y 3 M 9 D/M

UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389
Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 58963

Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 01:11PM Reported : 27/Nov/2023 02:24PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF IMMUNOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			

VITAMIN D (25 - OH VITAMIN D) , SERUM	6.32	ng/mL	30-100	CLIA

Kindly correlate clinically.

#### **Comment:**

#### BIOLOGICAL REFERENCE RANGES

VITAMIN D STATUS	VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY	<10
INSUFFICIENCY	10 - 30
SUFFICIENCY	30 – 100
TOXICITY	>100

The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency can also cause osteomalacia, which frequently affects elderly patients.

Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.

Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D, which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval of greater than 30 ng/mL is a target value established by the Endocrine Society.

#### **Decreased Levels:**

Inadequate exposure to sunlight.

Dietary deficiency.

Vitamin D malabsorption.

Severe Hepatocellular disease.

Drugs like Anticonvulsants.

Nephrotic syndrome.

Increased levels:

Vitamin D intoxication.

Page 11 of 15







UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 01:11PM Reported : 27/Nov/2023 02:15PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF IMMUNOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BOD	V DI LIS ANNITAL C	HECK ADVANC	ED HC MALE - TMT - DA	AN INDIA - EV2324
ANGOI LIMI - MILDIWITELE - I OLL BOD	T FEOS ANNOAL C	ILCK ADVANC	LD IIC MALL - IMII - FA	AN INDIA - 1 12324
Test Name	Result	Unit	Bio. Ref. Range	Method
i est Naille	Result	Unit	Bio. Rei. Ralige	Method
		!	!	!

VITAMIN B12 , SERUM	148	pg/mL	107.2-653.3	CLIA

#### **Comment:**

- Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes.
- The most common cause of deficiency is malabsorption either due to atrophy of gastric mucosa or diseases of terminal ileum.

  Patients taking vitamin B12 supplementation may have misleading results.
- A normal serum concentration of B12 does not rule out tissue deficiency of vitamin B12 .
- The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum B12 concentrations are normal.
- Increased levels can be seen in Chronic renal failure, Congestive heart failure, Leukemias, Polycythemia vera, Liver disease etc.





UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM
Received : 27/Nov/2023 06:36PM
Reported : 27/Nov/2023 09:02PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y PLUS ANNUAL C	HECK ADVANC	ED HC MALE - TMT - PA	AN INDIA - FY2324
Test Name	Result	Unit	Bio, Ref. Range	Method

-					
TOTAL PROSTATIC SPECIFIC ANTIGEN	0.840	ng/mL	0-4	CLIA	
(tPSA) . SERUM					

Page 13 of 15







Patient Name : Mr.ANUJ KUMAR

Age/Gender : 34 Y 3 M 9 D/M UHID/MR No : SCHI.0000016438

Visit ID : SCHIOPV23389

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 58963 Collected : 27/Nov/2023 10:23AM
Received : 27/Nov/2023 12:17PM

Reported : 27/Nov/2023 12:44PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

# DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (CUE)	, URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				·
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUNT	AND MICROSCOPY	<b>(</b>		
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 14 of 15







Patient Name

: Mr.ANUJ KUMAR

Age/Gender

: 34 Y 3 M 9 D/M

UHID/MR No

: SCHI.0000016438

Visit ID Ref Doctor : SCHIOPV23389

Emp/Auth/TPA ID

: Dr.SELF : 58963 Collected : 27/Nov/2023 10:23AM

Received : 27/Nov/2023 12:17PM

Reported : 27/Nov/2023 12:43PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF CLINICAL PATHOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BOD	Y PLUS ANNUAL C	HECK ADVANC	ED HC MALE - TMT - PA	AN INDIA - FY2324
Tool Name	Dogult	I I m i 4	Die Def Dense	Mathad

Test Name	Result	Unit	Bio. Ref. Range	Method

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick

URINE GLUCOSE(FASTING) NEGATIVE NEGATIVE Dipstick

\*\*\* End Of Report \*\*\*

Dr Tanish Mandal

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Lovekesh Monga M.B.B.S,M.D(Pathology) Consultant Pathologist.

Page 15 of 15





Jakin-

Name : Mr. Anuj Kumar

Age: 34 Y Sex: M

Address: prahladpur delhi

-- --- · p......ap ... ac...

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:SCHI.0000016438

OP Number: SCHIOPV23389
Bill No : SCHI-OCR-8691

Date : 27.11.2023 10:09

Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - TMT	
1	URINE GLUCOSE(FASTING)	
. 2	GAMMA GLUTAMYL TRANFERASE (GGT)	
3	PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	
- 4	HbA1c, GLYCATED HEMOGLOBIN	
5	ALKALINE PHOSPHATASE - SERUM/PLASMA	
$\epsilon$	LIVER FUNCTION TEST (LFT)	
7	X-RAY CHEST PA	
8	GLUCOSE, FASTING	
9	HEMOGRAM + PERIPHERAL SMEAR	
10	ENT CONSULTATION V	
11	CARDIAC STRESS TEST(TMT)	
12	FITNESS BY GENERAL PHYSICIAN	
13	DIET CONSULTATION	
14	COMPLETE URINE EXAMINATION	
15	URINE GLUCOSE(POST PRANDIAL)	
16	PERIPHERAL SMEAR	
17	ECG	
18	BLOOD GROUP ABO AND RH FACTOR	
19	VITAMIN B12	
20	LIPID PROFILE /	
21	BODY MASS INDEX (BMI)	
22	OPTHAL BY GENERAL PHYSICIAN	
23	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
24	ULTRASOUND - WHOLE ABDOMEN	
	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
26	DENTAL CONSULTATION V	
27	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	
28	VITAMIN D - 25 HYDROXY (D2+D3)	

TICA TOOM WHILD

Height: 169
Weight: 70
B.P: 120/80
Pulse: 80

#### FO Desk

From:

noreply@apolloclinics.info

Sent:

03 November 2023 12:24 rupaldovebird@gmail.com

To: Cc:

phc.klc@apollospectra.com; syamsunder.m@apollohl.com;

cc.klc@apollospectra.com

Subject:

Your Apollo order has been confirmed



## Dear ANUJ KUMAR .,

Namaste Team,

Greetings from Apollo Clinics,

With regards to the below request the below appointment is scheduled at SPECTRA NEHRU ENCLAVE clinic on 2023-11-25 at 09:25-09:30.

Payment Mode	Credit
Corporate Name	ARCOFEMI HEALTHCARE LIMITED
Agreement Name	ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN INDIA OP AGREEMENT
Package Name	[ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324]

<sup>&</sup>quot;As stated in the agreement terms, kindly carry all relevant documents such as HR Authorization Letter, Appointment Confirmation Mail, valid government ID proof, company ID card etc. along with you."

Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences.

Note: Also once appointment is booked, based on availability of doctors at clinics tests will happen, any pending test will happen based on doctor availability and clinics will be updating the same to customers.

Instructions to undergo Health Check:









Anuj Kumar 1989-08-18 Male

xxxxxxxx4633

# Address:

S/O Maheshwar Sharma E-253 GALI N-7
PUL PRAHLADPUR badarpur - South Delhi Delhi 110044





Tap to Zoom

आधार-आम आदमी का अधिकार

# Dr. Lalit Mohan Parashar

MS (ENT)

Ear, Nose, Throat Specialist and Head & Neck Surgeon

For Appointment :+91 11 40465555 Mob.:+91 9910995018 MCI No. 4774/85 ANUS NUMM

Apollo Spectra
HOSPITALS
Specialists in Surgery

34/m

NO LEADING INT COMPLAINTS

PRIVEN TIVE NEALTH CHIECK

OIE

Mosz - DNS +

( ASYMPTOMATIC)

Tunont - NM

RAS- B/L TM D

WAR REMOVED

VOICE, SPEEU MS MESNING ()

9M- TENT- NORM

T7/ 11/2027

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

# Apollo Specialty Hospital Pvt. Ltd.



27/11/2023 -

Mer. Anny Kumar, 34 Years Male,

C/C! Rigner Devilor Check ryp.

PDH!- N.R.

O/€!- Calculus ++.

Stains peusurd, brossly Carious,

Admised !- , Scaling

Extraction 8 4

Impland ffD net 4.

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

# **Apollo Specialty Hospital Pvt. Ltd.**



# DIGITAL X-RAY REPORT

NAME: ANUJ	DATE: 27.11.2023
UHID NO : 16438	AGE: 34YRS/ SEX: M

#### X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

24/11/23

Mr - Alning Lumos



100/6 - 00 ( maradad)

40- nip

J04/1

11 C16/0 WOD- To

defor have

DE Var

Id for the south


13 Ano 000

- 100 (V)

an Ve

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

# **Apollo Specialty Hospital Pvt. Ltd.**





NAME:	ANUJ KUMAR	AGE/SEX:	34	YRS./M
UHID:	16438			
REF BY :	APOLLO SPECTRA	DATE:-	27.11.	2023

### **ULTRASOUND WHOLE ABDOMEN**

Liver: Appears normal in size, and shows increased parenchymal echogenicity which is most likely due to fatty changes. Intrahepatic biliary radicles are not dilated. CBD and portal vein are normal in calibre.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

**Both Kidneys**: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Prostate: normal in size, weight 16.7 Gms. It is normal in echotexture with no breech in the capsule.

No free fluid seen.

IMPRESSION: FATTY CHANGES IN LIVER GRADE I

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRA Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



Patient Name

UHID

Conducted By: Referred By

: Mr. Anuj Kumar : SCHI.0000016438

: Dr. MUKESH K GUPTA

: SELF

Age OP Visit No

34 Y/M SCHIOPV23389 : 27-11-2023 17:10 Conducted Date

Protocol

Medication

Target Heart Rate Heart Rate Achieved Percentage of THR Achieved

Maximum Blood Pressure **Total Exercise Duration** Maximum Worked Attained Reason for termination

Bruce Protocol

186 BPM 164 BPM

88% 130/86 mmHg

06:22 Min. 08.00 Mets Max HR Attained.

#### Comments

- Basal ECG NSR.
- Appropriate HR response.
- Appropriate BP response.
- No significant changes with standing and hyperventilation.
- Good exercise tolerance.
- No significant ST segment depression over baseline during exercise or recovery period
- No crepts or rhonchi.
- Arrhythmia none.
- Chest pain absent.

#### Summary

- Test is negative for provocable myocardial ischemia.
- Good exercise tolerance.
- Appropriate BP response.

Please correlate clinically Not valid for medico legal purpose.



Dr. M K Gupta M.B.B.S, MD, FIACM Senior Consultant Cardiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

## **Apollo Specialty Hospital Pvt. Ltd.**

						04.4						
POLLO SPEC						Station						
EHRU ENCL	AVE					Telephor	ie:					
EW DELHI												
		EV	ERCIS	т отт	DESS	TEST	DEDU	рт				
		LX	EKC15	ESII	(ESS	ILSI	KEIO	1 1				
, , , , , , , , , , , , , , , , , , ,	ZIIMAD ANIII				DOB:	18.08.1989	)				Ш	
atient ID: 164	KUMAR, ANU	J			Age: 3							
leight: 169 cm					Gender							
Veight: 70 kg					Race: I							
Study Date: 27	.11.2023					ng Physici						
est Type:						ing Physic	ian:					
Protocol: BRU	CE				Lechni	cian:						H
Aedications:												
-												
Aedical Histor	y:											
Reason for L	Exercise Test:	1										
-												
Exercise Tes	st Summary											
		a.v				D.D.	C					
Phase Name	Stage Name	Time in Stage	Speed [mph]	Grade [ % ]	HR [ hpm ]	BP [ mmHg ]	Commen	U				
		III Stage	[ IIIpii ]	1 /0 1	[ opin ]	[5]						
RETEST	SUPINE	02:13	0.00	0.00	107	120/80						
	STANDING	01:04	0.00	0.00	90	120/80						
	HYPERV.	00:09	0.00	0.00	90 90							
EXERCISE	WARM-UP STAGE I	00:12 03:00	0.90 1.70	10.00	127	120/80						
EXERCISE	STAGE 2	03:00	2.50	12.00	151	130/86						
	STAGE 3	00:22	3.40	14.00	160	130/86						
RECOVERY		05:43	0.00	0.00		110/78						
	exercised acc	ording to t	he BRU	CE for $\epsilon$	5:22 mi	in:s. achi	eving a	work le	evel c	of N	1ax	. M
The nations		7.7	se to a m	aximal	heart ra	ate of 16	4 bpm.	This va	lue re	epre	sent	ts
The patient	heart rate of	/5 hnm ro			1	612	0/80  mp	л На г	ose to	ar	nax	im
The resting 1	heart rate of	/5 bpm ro	he restin	o blood	1 pressi	ire oi 1/	()()() [][]	1112 . 1		Jul	HULL	
The resting l maximal, ag	heart rate of 7 re-predicted b	neart rate. T	The restin	ig blood	pressi	ure of 12	V HR at	tained	OSC II	Jai	Hun	
The resting l maximal, ag	heart rate of	neart rate. T	The restin	ig blood	pressi	lue to Ma	ax HR at	ttained			nax	
maximal, ag pressure of	heart rate of ge-predicted h	neart rate. T	The restin	ig blood	pped c	lue to Ma	nx HR at	ttained		Jul	IIUA	
The resting l maximal, ag	heart rate of ge-predicted h	neart rate. T	The restin	ig blood	opped c	lue to Ma	nx HR at	ttained			II CA	

S: 8.00. % of the blood

HR Response to Exercise: appropriate.

BP Response to Exercise: normal resting BP - appropriate response.

Chest Pain: none.

Conc	lus	ion	S
------	-----	-----	---

Physician	Technician

																																D 7
,					RECOVERY			EXERCISE				PRETEST		Phase Name																	1:34:41pm	Patient ID: 16458 27.11.2023   1
					ERY		į	7 T)						ame																	Ĭ	23 .
						S	SO C	n	<	T.	S	S		S															2		رى دى	1408 N
						STAGE 3	TAGE 2	STAGE	WARM-UP	HYPERV	STANDING	SUPINE		Stage Name										Comment.	Kel. MD:	) : :	Medical History	lest Keason		Meds:	34 yrs Indian	s Male 16
									P		á			ાલ													otste	: 011.			dian	169 cm
					05:43	00:22	03:00	03:00	00:12	00:09	01:04	02:13	in Stage	Time										Test Type.	Ordering MD		콧					70 kg
													ge											oc.	MU	9						
					0.	<u>ر</u> ي	) :		0	0	0	0	[ mph]	Sp																		
					0.00	40	2.50	70	90	0.00	0.00	0.00	ph ]	Speed																		
														G																		
					0.00	14.00	12.00	000	0.00	0.00	0.00	0.00	[%]	rade																		
													_ Z	Wo																		
					1.0	8.0	7.0	46	1	1.0	1.0	0	METS	Workload																		
						16	<u>5</u> i	5	90	90	90	107	[ bpm	Ħ																		
						0		7				7	B 	~																		
					110/78	130/86	130/86	08/07			120/80	120/80	mmHg	ВР	Location	Room:	Exerci	Resting EC		Reason	ORS d	ST/HR	VE rec	HR rec	OL/IIV	SI/HK	AIIIYI	\\ \	Max ST: 100 mm 0.47 mV/s in III: RECOVERY	Max BP: 130/86 mmHg BP at rest: 120/80 Max RPP: 21320 mmHg*opm	Max HR: 164 bpm 88% of max predicted 186 bpm HR at rest; 75	BRUCE: Exercise Time 06:22
															)n: * (		se: no	g EC(	2 V.	is for	uratio	hyste	overy:	overv	Slobe	Index			T. H	P: 130	R: 164	E: Exe
						20800	19630	15240	10800	10800	10800	12840	mmHg*bp	RPP	*		rmal re	i: nor		Term	1. BAS	resis: (	E recovery: 0 VE/min	R recovery: 28 bpm	.0.17	70.1.3	1.1.	)	OFKIOZ	/86 mr	t bpm	rcise 1
													bp				sting	nal.				.023	∄. ∃.	3	70/0	0/47	JA C	0000	0: 8.0 0 4	SHu	88%	ime
					0	0	0	0	0	0	0	0	[/min]	VE			xercise: normal resting BP - appropriate response. Chest Pain: none.	esting ECG: normal. HR Response to Exercise: appropriate.		easons for Termination: Max HR attained	RS duration: BASELINE: 88 ms. PEAK EX: 88 ms. REC: 90 ms	C/HR hysteresis: 0.023 mV (V5)			bill (III	pin	). <u>I</u> .	· 1 h		BP at	of ma	06:22
														S			pprop	spons		X II I	ms. P	5)			,			-	- J	rest:	x pre	
					1	-0.70	-0.60	0 15	0.50	0.50	0.50	0.55	mm ]	STLevel			riate re	e to E		attaine	FAK							, 1,000	- REC	120/8	licted	
																	espons	xercis		ď	EX:							· ·	OVE	3	186 bj	
														Comment			se. Ch	se: api			sms.									ax RP	pm I	
																	iest P	propri			RHC								0-08	P: 21	IR at	
																	ain: n				90 n									320 m	rest.	
																	lone.	Re Re			S									3Hmu	75	
																		BP Response to												*bpn		
																		se to														

Attending MD: